RenovoRx, Inc.
RNXT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $43 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $43 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $6,025 | $5,667 | $4,301 | $3,039 |
| G&A Expenses | $4,988 | $5,729 | $5,649 | $2,632 |
| SG&A Expenses | $4,988 | $5,729 | $5,649 | $2,632 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,013 | $11,396 | $9,950 | $5,671 |
| Operating Income | -$10,970 | -$11,396 | -$9,950 | -$5,671 |
| % Margin | -25,511.6% | – | – | – |
| Other Income/Exp. Net | $2,156 | $1,164 | $61 | -$653 |
| Pre-Tax Income | -$8,814 | -$10,232 | -$9,889 | -$6,324 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,814 | -$10,232 | -$9,889 | -$6,324 |
| % Margin | -20,497.7% | – | – | – |
| EPS | -0.37 | -0.5 | -0.54 | -0.4 |
| % Growth | 26% | 7.4% | -35% | – |
| EPS Diluted | -0.37 | -0.5 | -0.54 | -0.4 |
| Weighted Avg Shares Out | 23,606 | 20,581 | 18,103 | 17,868 |
| Weighted Avg Shares Out Dil | 23,606 | 20,581 | 18,103 | 17,868 |
| Supplemental Information | – | – | – | – |
| Interest Income | $384 | $0 | $57 | $0 |
| Interest Expense | $0 | $108 | $57 | $834 |
| Depreciation & Amortization | $0 | $6 | $6 | $9 |
| EBITDA | -$10,970 | -$11,390 | -$9,944 | -$5,481 |
| % Margin | -25,511.6% | – | – | – |